Enterprise Value

-479.6M

Cash

1.847B

Avg Qtr Burn

-90.5M

Short % of Float

5.70%

Insider Ownership

14.26%

Institutional Own.

75.95%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Sotrovimab VIR-7831 (GSK4182136) Details
COVID-19, Infectious disease

Phase 3

Update

VIR-3434 +/- VIR-2218 +/- PEG-IFNα Details
Infectious disease, Hepatitis B

Phase 2

Data readout

VIR-3434 + VIR-2218 Details
Infectious disease, Hepatitis B

Big Mover™

Susp. Mover™

Phase 2

Data readout

VIR-3434 + VIR-2218 Details
Infectious disease, Hepatitis Delta Virus

Big Mover™

Susp. Mover™

Phase 2

Data readout

VIR-2482 (Universal prophylaxis) Details
Influenza, Infectious disease

Phase 2

Update

VIR-1388 (HVTN 142) Details
Infectious disease, Human immunodeficiency virus, Vaccine

Phase 1

Data readout

VIR-1111 Details
Infectious disease, Human immunodeficiency virus, Vaccine

Phase 1

Update

Sotrovimab VIR-7831 (GSK4182136) Details
COVID-19, Infectious disease

Failed

Discontinued